Phesi

Phesi is a clinical data science company specializing in AI-driven solutions for optimizing clinical trials.

Reviewed by 7wData
Share Email

On this page

Profile

Phesi uses AI and real-world data to optimize clinical trial design and execution.

Phesi is a clinical data science company specializing in AI-driven solutions for optimizing clinical trials. Founded with the mission to accelerate drug development, Phesi leverages its proprietary database of real-world data from over 325 million patients and 485,000 curated clinical trials. The company’s platform, Trial Accelerator, focuses on improving protocol design, patient population profiling, and site selection, aiming to reduce trial failures and streamline development timelines.

Phesi serves more than 40 pharmaceutical and biotech companies, including industry leaders like Takeda and Sanofi, helping them navigate the complexities of clinical trials with data-driven insights. The company has been recognized for its innovative approach, including awards for its AI-powered solutions. Phesi’s recent emphasis on digital twins and external control arms reflects its commitment to advancing precision medicine and reducing the cost and time of traditional trials. The global digital twins in healthcare market, where Phesi is a key player, is projected to grow from $1.9 billion in 2025 to $33.4 billion by 2035, driven by increasing demand for personalized medicine and automated decision-making.

Track Phesi and 240+ vendors.

48k+ subscribers read the daily AI & data note. One email, both newsletters. Unsubscribe anytime.

Who buys this

  • Pharmaceutical companies
  • Biotech firms
  • Clinical research organizations (CROs)
  • Healthcare providers
  • Academic research institutions

Publicly disclosed clients

  • Takeda
  • Sanofi

Strengths and what to watch

Strengths

  • Proprietary database with real-world data from 325 million patients
  • AI-driven predictive modeling for trial optimization
  • Award-winning platform trusted by leading pharmaceutical companies

Watch for

  • High dependence on pharmaceutical industry clients
  • Competition from other AI-driven clinical trial platforms
  • Regulatory scrutiny around AI and data privacy in healthcare

Key Information

Frequently Asked Questions

What is Phesi and what does it do?

Phesi is a clinical data science company using AI and real-world data from 325 million patients to optimize clinical trials. Its Trial Accelerator platform helps pharmaceutical firms improve protocol design, patient profiling, and site selection, reducing trial failures and accelerating drug development timelines.

How does Phesi use AI in clinical trials?

Phesi's AI analyzes its proprietary database of 485,000 clinical trials and real-world patient data to predict optimal trial designs. This includes identifying suitable patient populations, forecasting recruitment challenges, and modeling outcomes—reducing costs and improving success rates for pharmaceutical companies.

What are digital twins in Phesi's context?

Phesi employs digital twins—virtual patient models based on real-world data—to simulate clinical trial outcomes. This allows researchers to test scenarios before actual trials, improving protocol design and serving as external control arms, particularly valuable in rare disease studies.

Which major companies use Phesi's services?

Phesi serves over 40 pharmaceutical and biotech firms, including industry leaders like Takeda and Sanofi. These clients leverage Phesi's AI-driven insights for trial optimization across various therapeutic areas and development phases.

How does Phesi's real-world data improve trials?

Phesi's database contains de-identified records from 325 million patients, enabling precise patient population profiling. This helps design trials with appropriate inclusion criteria, predict recruitment rates, and benchmark against historical outcomes—reducing protocol amendments and site selection errors.

What makes Phesi different from traditional trial methods?

Unlike traditional trial approaches relying on limited datasets, Phesi combines AI with comprehensive real-world evidence. This data-driven method identifies optimal protocols earlier, predicts recruitment challenges, and creates digital twin control arms—potentially cutting development timelines while maintaining regulatory compliance.

Sources

  1. www.phesi.com — Proprietary database with real-world data from 325 million patients
  2. www.businesswire.com — Projected growth of the digital twins in healthcare market
  3. www.fiercebiotech.com — AI-driven solutions for clinical trial optimization
  4. www.clinicalleader.com — Focus on patient-centric trial design and execution